Close Menu

NEW YORK (GenomeWeb) – BRCA2 mutations are associated with poorer treatment responses and outcomes among men with aggressive prostate cancer, according to a new study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.